Dr. Angelika Vlachou

Partner

Dr. Angelika Vlachou

Partner

Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.

Contact

Telefon:
+49 (0) 30 – 4036648 – 50

Portfolio

Posts & mentions

Press
29. September 2022

Dr. Angelika Vlachou and Stefanie Grüter appointed partners at High-Tech Gründerfonds

Dr. Angelika Vlachou and Stefanie Grüter to become partners at High-Tech Gründerfonds effective 1 October 2022Dr. Angelika Vlachou to further expand her duties within the Life Sciences unit at HTGF’s Berlin office in her new role as partnerStefanie Grüter to assume responsibility for marketing, communications and relationship management in her new position Bonn/Berlin, 29 September 2022 – High-Tech Gründerfonds, leading seed investor in Germany, has appointed Stefanie Grüter
 
Press
KUPANDO Logo
26. September 2022

Kupando raises €13 million in Series A funding round

Financing led by Remiges Ventures, co-led by LifeCare Partners, with additional investments by Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors and undisclosed family offices.Proceeds to be used to complete IND-enabling work and initiate clinical development. Schönefeld/Berlin, 26. September 2022 – Kupando, a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, anno
 
Press
7. September 2022

faCellitate, a BASF spin-off, closes a €3.7m seed round led by SARSTEDT and HTGF

Proprietary intelligent polymer surface coating platform enables development of first-in-class lab materials for modern cell culture applications Closing of seed round completed raising €3.7 million from SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft and Chemovator.faCellitate has developed an intelligent and ultra-low attachment polymer surface coating platform. The first launched product thereof is targeting 3D cell culture, enabling
 
Press
9. February 2022

Lindis Blood Care successfully closes follow-on financing round 

Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitmentFunds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activitiesCATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood Hennigsdorf, Germa